Anxiety in oncology outpatients is associated with perturbations in pathways identified in anxiety focused network pharmacology research
- PMID: 38012456
- PMCID: PMC10682221
- DOI: 10.1007/s00520-023-08196-2
Anxiety in oncology outpatients is associated with perturbations in pathways identified in anxiety focused network pharmacology research
Abstract
Purpose: Evaluate for perturbed signaling pathways associated with subgroups of patients with low versus high levels of state anxiety. These pathways were compared to the pathways identified across eight network pharmacology studies of the anxiolytic effect(s) of a variety of compounds.
Methods: Adult outpatients had a diagnosis of breast, gastrointestinal, gynecological, or lung cancer; had received chemotherapy within the preceding four weeks; and were scheduled to receive at least two additional cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct anxiety profiles based on Spielberger State Anxiety Inventory scores that were obtained six times over two cycles of chemotherapy. Blood samples were processed using RNA sequencing (i.e., RNA-seq sample, n = 244) and microarray (i.e., microarray sample; n = 256) technologies. Pathway perturbations were assessed using pathway impact analysis. Fisher's combined probability method was used to combine test results using a false discovery rate of 0.01.
Results: In the RNA-seq sample, 62.3% and 37.7% of the patients were in the low- and high-anxiety classes, respectively. In the microarray sample, 61.3% and 38.7% were in the low and high-anxiety classes, respectively. Forty-one perturbed signaling pathways were identified. Eight of these pathways were common to those identified in the network pharmacology studies.
Conclusions: Findings increase our knowledge of the molecular mechanisms that underlie anxiety in patients receiving chemotherapy. This study provides initial insights into how anxiety in patients with cancer may share common mechanisms with anxiety in patients with other clinical conditions.
Keywords: Anxiety; Cancer; Chemotherapy; Pathway impact analysis.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Sleep disturbance is associated with perturbations in immune-inflammatory pathways in oncology outpatients undergoing chemotherapy.Sleep Med. 2023 Jan;101:305-315. doi: 10.1016/j.sleep.2022.11.014. Epub 2022 Nov 21. Sleep Med. 2023. PMID: 36470166 Free PMC article.
-
Perturbations in Neuroinflammatory Pathways Are Associated With a Worst Pain Profile in Oncology Patients Receiving Chemotherapy.J Pain. 2023 Jan;24(1):84-97. doi: 10.1016/j.jpain.2022.08.007. Epub 2022 Sep 15. J Pain. 2023. PMID: 36115520 Free PMC article.
-
Perturbations in inflammatory pathways are associated with shortness of breath profiles in oncology patients receiving chemotherapy.Support Care Cancer. 2024 Mar 26;32(4):250. doi: 10.1007/s00520-024-08446-x. Support Care Cancer. 2024. PMID: 38532105 Free PMC article.
-
Telephone interventions for symptom management in adults with cancer.Cochrane Database Syst Rev. 2020 Jun 2;6(6):CD007568. doi: 10.1002/14651858.CD007568.pub2. Cochrane Database Syst Rev. 2020. PMID: 32483832 Free PMC article.
-
Exploring the potential mechanism of Kaixinsan powder for the same pathogenesis of PTSD and anxiety based on network pharmacology and molecular docking: A review.Medicine (Baltimore). 2023 Nov 17;102(46):e35869. doi: 10.1097/MD.0000000000035869. Medicine (Baltimore). 2023. PMID: 37986356 Free PMC article. Review.
References
-
- Brunckhorst O, Hashemi S, Martin A, George G, Van Hemelrijck M, Dasgupta P, Stewart R, Ahmed K. Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2020;24:281–289. - PubMed
-
- Hashemi S-M, Rafiemanesh H, Aghamohammadi T, Badakhsh M, Amirshahi M, Sari M, Behnamfar N, Roudini K. Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis. Breast Cancer. 2020;27:166–178. - PubMed
-
- Linden W, Vodermaier A, MacKenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Dis. 2012;141:343–351. - PubMed
-
- Vargas-Roman K, Diaz-Rodriguez CL, Canadas-De la Fuente GA, Gomez-Urquiza JL, Ariza T, De la Fuente-Solana EI. Anxiety prevalence in lymphoma: a systematic review and meta-analysis. Health Psychol. 2020;39:580–588. - PubMed